Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Therapeutic antitumor antibodies treat cancer by mobilizing both innate and adaptive immunity. CD47 is an antiphagocytic ligand exploited by tumor cells to blunt antibody effector functions by transmitting an inhibitory signal through its receptor signal regulatory protein alpha (SIRPα). Interferenc...
Main Authors: | Sockolosky, Jonathan T. (Author), Ho, Chia Chi M. (Author), Almo, Steven C. (Author), Garcia, K. Christopher (Author), Dougan, Michael (Contributor), Kauke, Monique Jacqueline (Contributor), Ploegh, Hidde (Contributor), Ingram, Jessica R. (Contributor) |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Whitehead Institute for Biomedical Research (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor) |
Format: | Article |
Language: | English |
Published: |
National Academy of Sciences (U.S.),
2016-12-02T20:15:13Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
An antitumor peptide RS17‐targeted CD47, design, synthesis, and antitumor activity
by: Xinmin Wang, et al.
Published: (2021-03-01) -
A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
by: Fangzhen Lin, et al.
Published: (2021-01-01) -
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
by: Rashidian, Mohammad, et al.
Published: (2018) -
Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells
by: Feng Li, et al.
Published: (2018-02-01) -
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
by: Demet Candas-Green, et al.
Published: (2020-09-01)